Aileron Therapeutics is developing first-in-class Stapled Peptide therapeutics to engage disease targets and pathways that are undruggable by existing technologies. Stapled Peptide therapeutics have the potential to become a major class of drugs for oncology and other diseases. Aileron’s lead drug development candidate, ALRN-6924, is designed to reactivate wild-type p53, the body's first line of defense against cancer.
Apellis Pharmaceuticals is a clinical stage biopharmaceutical company treating autoimmune and inflammatory diseases by inhibition of the complement system, a cascade of interacting proteins and is an integral component of the immune system. The Apellis lead product candidates are being evaluated in clinical trials to treat ophthalmic, orphan and pulmonary conditions.
Founded by a highly experienced management team, Atea Pharmaceuticals, Inc. is an emerging biopharmaceutical company which is engaged in the discovery and development of novel antiviral therapeutics.
Bellicum (Nasdaq: BLCM) is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular therapies using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines.
Clearside Biomedical is developing first-in-class drug therapies to treat blinding diseases of the eye. Clearside’s clinical product candidates focus on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space, or SCS, adjacent to the choroid, using the Company’s proprietary microinjector.
G1 Therapeutics is developing novel, small-molecule therapies that target cyclin-dependent kinases, or CDKs, a family of proteins that plays an important role in the growth and proliferation of cells. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications.
Kezar Life Sciences
Kezar Life Sciences is discovering and developing innovative new therapies targeting protein homeostasis. Kezar’s lead program, KZR-616, is a selective inhibitor of the immunoproteasome for the treatment of autoimmune disorders. The work that led to KZR-616 was developed at Onyx Pharmaceuticals and Amgen by the Kezar scientific team that discovered and developed Kyprolis, a non-selective proteasome inhibitor for the treatment of malignancies. Kezar’s second program targets protein secretion, which is regulated by the Sec61 translocon on the endoplasmic reticulum.
Molecular Templates is focused on the discovery and development of a new class of Antibody Drug Conjugates (ADCs) with distinct advantages over existing ADC approaches. This biologic platform technology is being used to develop multiple therapies across a wide range of cancers. The Company’s lead compound, MT-3724, an immunotoxin targeting CD20, is in a Phase I study for the treatment of non-Hodgkin’s lymphoma and DLBCL.
Orionis Biosciences was founded in 2015 by an experienced management team with two platforms, one a small molecule drug discover platform and the other a platform focused on novel oncology therapeutics.
Selecta Biosciences is developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Selecta’s proprietary Synthetic Vaccine Particle (SVP) platform creates a novel paradigm in immunotherapeutics and vaccines, enabling completely new applications while offering the potential of improved efficacy and safety profiles. Selecta’s SVP is a product engine that has the potential to unlock the full therapeutic value of biologic therapies.
Trefoil Therapeutics is developing therapeutic agents for treatment of corneal endothelial dystrophy, specifically Fuchs’ dystrophy and other endothelial diseases of the eye. Patients with Fuchs’ dystrophy experience degenerative changes to the endothelium of the cornea. Normally, the endothelium contributes to proper vision by pumping excess fluid out of the eye that could cause corneal swelling. Fuchs’ corneal dystrophy leads to a decrease in corneal endothelial cell count and function, ultimately causing edema and loss of vision.
Synlogic is developing several programs categorized to inborn errors of metabolism, immunomodulation and metabolic disease which synthetic biotic can be used for the treatment.
Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Arvinas is a biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTACTM protein degraders, or Proteolysis-Targeting Chimera, work by inducing the cell’s own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins.
Kymera Therapeutics is pioneering a game-changing new therapeutic modality and platform with the potential to transform drug discovery and deliver breakthrough medicines for previously untreatable diseases. Kymera is focused on using targeted protein degraders to degrade proteins involved in the pathogenesis of inflammatory diseases and cancer.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing our proprietary drug discovery and development engine, we develop highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases.
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. Arcellx’s vision is to bring ARC-SparX platform cell therapies to millions of patients who can self-administer prescribed SparX proteins under the care of academic and community practices.
Amphivena Therapeutics, Inc. is a clinical-stage, immuno-oncology company with a novel platform of T cell engagers (Amphivena ReSTORE™) that directly targets myeloid derived suppressor cells (MDSC), thus relieving cancer-induced immune suppression while controlling cytokine release syndrome (CRS).
Xilio’s proprietary technology allows us to create novel immunotherapies that preferentially bind their targets in tumors while minimizing activity in healthy non-tumor tissues. To engineer our tumor-selective therapies, we start with a highly potent cytokine or antibody which is then inactivated by fusing it to a “blocking domain”.
HotSpot Therapeutics has designed the first technology platform that systematically uncovers the privileged allosteric sites used by nature to control proteins. HotSpot is industrializing the discovery of medicines that leverage nature’s regulatory hotspots to treat diseases in entirely new ways.
Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. We are focused on rapidly advancing our pipeline of promising product candidates and on further expanding our portfolio to execute on our mission.
Chameleon's patented EVADER platform technology is a brand-new approach to gene therapy that overcomes existing treatment barriers. EVADER technology effectively cloaks the current standard of care treatment capsid by: Shielding the capsid From antibodies, Reducing antibody production, Masking foreign proteins to increase tolerance.
EvolveImmune is uncovering new biology to create tomorrow’s precision immunotherapies. Our proprietary CITII(TM) platform integrates multiple elements of CRISPR immune cell screening and validation techniques to discover first-in-class targets and accelerate the development of novel biologics to treat cancer and autoimmune disease.
Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.